ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 2257

Patient and Clinical Characteristics Associated with Increased Willingness to Adopt RA Treatment After an Educational Intervention: An Analysis of the Confident Treatment Decisions for Living with Rheumatoid Arthritis (CONTROL-RA) Trial

Adam Taylor1, Lang Chen 1, Ronan O'Beirne 2, Joshua Melnick 3, Eric Ruderman 4, Jeffrey Curtis 1 and Maria Danila 1, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, 3University of Alabama at Birmingham, Birmimgham, AL, 4Northwestern University Feinberg School of Medicine, Division of Rheumatology, Evanston, IL

Meeting: ACR/ARP Annual Meeting 2019

Keywords: Behavioral strategies and rheumatoid arthritis (RA)

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Patient Outcomes, Preferences, & Attitudes Poster II: Patient Preferences, Beliefs, & Experiences

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The treat to target (T2T) treatment strategy is associated with better clinical outcomes in patients with rheumatoid arthritis (RA). We have previously found that a direct-to-patient video intervention aimed to increase knowledge about T2T was associated with increased willingness to adopt RA treatment. The goal of this study was to evaluate patient and clinical characteristics associated with improved willingness to adopt treatment.

Methods: The CONTROL-RA trial, as previously reported, enrolled participants with self-reported RA, with RAPID 3 >4 (range 0-10) and without potentially confounding conditions or who had been using disease modifying anti-rheumatic drugs (DMARDs) in the past 6 months. Outcomes were collected using compensated surveys. Participants completed a baseline survey, viewed the educational intervention and completed the follow up survey immediately after. Intervention group participants viewed up to 6 videos (minimum of 2, mean duration 2 min) on topics relevant to T2T. We performed a multivariate analysis, where the primary outcome was pre-post difference in patient-reported willingness to adopt treatment. The following factors were considered: extent of engagement (e.g. high engagement group watched >80% of each of the 6 videos vs low engagement group watched less), age, sex, race, prior biologic/DMARD use, general health, health literacy, familiarity with T2T, patient global assessment, patient acceptable symptom state (PASS), decision conflict about treatment change (decision conflict scale, lower score is better), readiness for treatment change (precaution adoption process model) and personal attitudes favoring medications (10 items surveying patient attitudes regarding acceptable medication risks vs benefits; higher score is more favorable).

Results: Responses of 104 participants in the intervention group were analyzed (Table 1). Participants were 92% white, 92% women, with a mean age of 49 years. A total of 80 (77%) participants were classified in the high engagement group. Participants classified in the high engagement group had higher baseline willingness to adopt treatment than those in the low engagement group (7.1 vs 5.5, p=0.006). The pre-post difference in willingness to adopt treatment was 0.6 in the high engagement group and 0.3 in the low engagement group (p = 0.57). In multivariable models the level of engagement with the intervention was not associated with improved willingness to adopt treatment (p=0.14). Lower baseline level of willingness to change RA treatment, older age and personal attitudes favoring medications were associated with improved willingness to adopt RA treatment (Table 2).

Conclusion: We observed a high level of engagement and were thus not able to discern a dose-response relationship between our intervention and improved willingness after the intervention. Interestingly, those with higher willingness to change treatment were more likely to view the educational intervention, suggesting that those who are less open to treatment change may need additional support to get involved with this type of educational program.


Table 1.


Disclosure: A. Taylor, None; L. Chen, None; R. O'Beirne, None; J. Melnick, None; E. Ruderman, Pfizer, 2; J. Curtis, AbbVie, 2, 5, Abbvie, 2, 5, AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Lilly, Janssen, Myriad, Pfizer, Regeneron, Roche, and UCB, 2, 5, Amgen, 2, 5, Amgen Inc., 2, 5, BMS, 2, 5, Bristol-Myers Squibb, 2, 5, Corrona, 2, 5, Crescendo, 2, 5, Eli Lilly, 2, 5, Eli Lilly and Company, 2, 5, Genentech, 2, 5, Janseen, 5, Janssen, 2, 5, Janssen Research & Development, LLC, 2, Lilly, 2, 5, Myriad, 2, 5, Patient Centered Outcomes Research Insitute (PCORI), 2, Pfizer, 2, 5, Radius Health, Inc., 9, Regeneron, 2, 5, Roche, 2, 3, 5, Roche/Genentech, 5, UCB, 2, 5; M. Danila, Pfizer, 2, Sanofi Regeneron, 5.

To cite this abstract in AMA style:

Taylor A, Chen L, O'Beirne R, Melnick J, Ruderman E, Curtis J, Danila M. Patient and Clinical Characteristics Associated with Increased Willingness to Adopt RA Treatment After an Educational Intervention: An Analysis of the Confident Treatment Decisions for Living with Rheumatoid Arthritis (CONTROL-RA) Trial [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/patient-and-clinical-characteristics-associated-with-increased-willingness-to-adopt-ra-treatment-after-an-educational-intervention-an-analysis-of-the-confident-treatment-decisions-for-living-with-rhe/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARP Annual Meeting 2019

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-and-clinical-characteristics-associated-with-increased-willingness-to-adopt-ra-treatment-after-an-educational-intervention-an-analysis-of-the-confident-treatment-decisions-for-living-with-rhe/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology